Schaller, M
Unlike peptides that act through a single receptor target, BPC-157 is studied for its multi-pathway (pleiotropic) interactions within biological systems
This means cagrilintide and GLP-1 agonists are not competing for the same mechanism they are engaging the appetite-regulation system through separate but reinforcing pathways, which underpins the rationale for their combination
However, clinically significant anxiety seemed to have been reduced
Visual Format: Approved vs investigational status map Key Labels: Cosmetic product, compounded peptide, non-injectable route, injectable route, FDA safety concern, approved drug label, regulatory standards, product category Suggested Layout: Use a horizontal status map with four blocks: Cosmetic context, Non-injectable compounding review, Injectable safety concern, and Approved drug labeling. Add a note that product category changes evidence and safety interpretation
Best fit Focus, Memory research, Calm cognition Selank should be evaluated by goal fit, safety fit, evidence strength, and provider oversight